Sat, Oct 25, 2014, 9:03 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Calmare Therapeutics Incorporated Message Board

  • alumilli alumilli Aug 22, 2011 11:42 AM Flag

    I'm back

    after teaching courses in Brazil. I still see that CTT is a one-product company; that Nano is entitled to $750,000; that the Scott lawsuit is still pending; and that the employee count is way down. It appears that a select few are merely clipping coupons until the coompany folds.

    Has there been any good news lately?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • driver

      for your information, alumilli has been a long time poster on the CTT board, but also a very bitter poster whose identity is, to some extent, revealed by the monicker, i.e., University of ILLInois ALUMnus. However, many of us have suspected several points:
      1) not a female
      2) someone who had a lot to do with an early patent that the original firm University Patents was marketing, etc, specifically the Plato system developed at U of Ill -Urbana

      Most of the time this poster emerges from his/her cave to bash a company that has morphed so many times it is a wonder he has anyone to hate there anymore other than persisting in this bitterness aimed, believe it or not, at someone who preceded Nano by several generations. This is more like a Hatfield-McCoy fued where no one recalls what started it, although I am sure alumilli, if he/she wanted to, could tell all. Instead, you have the bi-annual bashing before this groundhog goes back into the den and hibernates once more

    • You're the one to blame for that aren't you Mr. Hypocrite. "Spammers aren't welcome here."

    • No internet in Brazil? I've been on this board 2 years, don't recognize your name?

    • You are one of the few without cloudy vision.

      • 1 Reply to plangleyxl
      • Wow, look at this:

        Newsletter
        Monday, Aug 22, 2011
        MDLinx Pain

        1. Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline–Based Drug Management: Results of a Pilot, Randomized, Controlled Trial
        Journal of Pain and Symptom Management
        2. A Comparative Efficacy of Amitriptyline, Gabapentin, and Pregabalin in Neuropathic Cancer Pain: A Prospective Randomized Double–Blind Placebo–Controlled Study
        American Journal of Hospice and Palliative Medicine
        3. Duloxetine, Pregabalin, and Duloxetine Plus Gabapentin for Diabetic Peripheral Neuropathic Pain Management in Patients With Inadequate Pain Response to Gabapentin: An Open–Label, Randomized, Noninferiority Comparison
        Mayo Clinic Proceedings
        >>See the rest of this Month's Top Read

 
CTTC
0.23+0.02(+9.47%)Oct 24 11:41 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.